NUVL
Price
$107.84
Change
+$6.67 (+6.59%)
Updated
Jan 14 closing price
Capitalization
8.37B
48 days until earnings call
Intraday BUY SELL Signals
PCVX
Price
$48.51
Change
+$2.49 (+5.41%)
Updated
Jan 14 closing price
Capitalization
6.35B
46 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NUVL vs PCVX

Header iconNUVL vs PCVX Comparison
Open Charts NUVL vs PCVXBanner chart's image
Nuvalent
Price$107.84
Change+$6.67 (+6.59%)
Volume$574.58K
Capitalization8.37B
Vaxcyte
Price$48.51
Change+$2.49 (+5.41%)
Volume$686.16K
Capitalization6.35B
NUVL vs PCVX Comparison Chart in %
NUVL
Daily Signal:
Gain/Loss:
PCVX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NUVL vs. PCVX commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Hold and PCVX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (NUVL: $107.84 vs. PCVX: $48.51)
Brand notoriety: NUVL and PCVX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 88% vs. PCVX: 51%
Market capitalization -- NUVL: $8.37B vs. PCVX: $6.35B
NUVL [@Biotechnology] is valued at $8.37B. PCVX’s [@Biotechnology] market capitalization is $6.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whilePCVX’s FA Score has 0 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • PCVX’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than PCVX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 5 TA indicator(s) are bullish while PCVX’s TA Score has 5 bullish TA indicator(s).

  • NUVL’s TA Score: 5 bullish, 4 bearish.
  • PCVX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both NUVL and PCVX are a good buy in the short-term.

Price Growth

NUVL (@Biotechnology) experienced а +0.95% price change this week, while PCVX (@Biotechnology) price change was +5.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

PCVX is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($8.38B) has a higher market cap than PCVX($6.35B). NUVL YTD gains are higher at: 7.207 vs. PCVX (5.137). NUVL has higher annual earnings (EBITDA): -398.38M vs. PCVX (-686.1M). PCVX has more cash in the bank: 1.71B vs. NUVL (943M). NUVL (0) and PCVX (0) have equivalent revenues.
NUVLPCVXNUVL / PCVX
Capitalization8.38B6.35B132%
EBITDA-398.38M-686.1M58%
Gain YTD7.2075.137140%
P/E RatioN/AN/A-
Revenue00-
Total Cash943M1.71B55%
Total DebtN/A84.4M-
TECHNICAL ANALYSIS
Technical Analysis
NUVLPCVX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 17 days ago
77%
Bearish Trend 17 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signal:
Gain/Loss:
PCVX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PSSPX27.760.15
+0.54%
Principal SmallCap S&P 600 Index R5
RIDCX26.640.12
+0.45%
American Funds Income Fund of Amer R3
JNVIX16.940.06
+0.36%
Jensen Quality Mid Cap I
MDVYX8.520.03
+0.35%
MassMutual Diversified Value Svc
VVIPX16.49-0.09
-0.54%
Voya VACS Index S

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with RVMD. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+6.59%
RVMD - NUVL
61%
Loosely correlated
+1.06%
XNCR - NUVL
60%
Loosely correlated
+3.66%
IDYA - NUVL
58%
Loosely correlated
+5.53%
XENE - NUVL
57%
Loosely correlated
+3.02%
VRDN - NUVL
56%
Loosely correlated
+5.60%
More

PCVX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PCVX has been loosely correlated with TSHA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PCVX jumps, then TSHA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCVX
1D Price
Change %
PCVX100%
+5.41%
TSHA - PCVX
50%
Loosely correlated
+2.86%
IDYA - PCVX
46%
Loosely correlated
+5.53%
NUVL - PCVX
45%
Loosely correlated
+6.59%
MRNA - PCVX
44%
Loosely correlated
+2.47%
BEAM - PCVX
44%
Loosely correlated
+2.49%
More